Spots Global Cancer Trial Database for prostate adenocarcinoma
Every month we try and update this database with for prostate adenocarcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC | NCT03494803 | Prostate Cancer Prostate Adenoc... Prostate Cancer... | 18 Years - 90 Years | HKGepitherapeutics | ||
| Mild Hypofractionation With Proton Therapy or Intensity Modulated Radiation Therapy (IMRT) for Intermediate-Risk Prostate Cancer | NCT01352429 | Prostate Adenoc... | Proton Therapy IMRT | 18 Years - | Abramson Cancer Center at Penn Medicine | |
| Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer | NCT01120236 | Prostate Adenoc... Recurrent Prost... Stage IV Prosta... | Bicalutamide Cixutumumab Goserelin Aceta... Laboratory Biom... Leuprolide Acet... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Active Surveillance for Low Risk Prostate Cancer | NCT04146077 | Prostate Cancer Prostate Adenoc... | 50 Years - 75 Years | I.M. Sechenov First Moscow State Medical University | ||
| High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma | NCT04945642 | Prostate Adenoc... Stage IIB Prost... Stage IIC Prost... Stage III Prost... Stage IIIA Pros... Stage IIIB Pros... Stage IIIC Pros... Stage IVA Prost... | High-Dose Rate ... Stereotactic Bo... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| PROState Pathway Embedded Comparative Trial | NCT04400656 | Prostate Cancer Non-metastatic ... Metastatic Pros... Prostate Adenoc... Metastatic Pros... Prostate Cancer... | 18 Years - | Imperial College London | ||
| Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence | NCT03396874 | Prostate Cancer Prostate Adenoc... Prostate Cancer... Prostate Cancer... | 68Ga-PSMA | 18 Years - | University of Michigan | |
| Expanded Access to Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrent Prostate Cancer | NCT05415228 | Prostate Adenoc... | 68Ga-PSMA-11 | 18 Years - | University of Michigan | |
| Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation | NCT05806515 | Prostate Adenoc... Stage IIIB Pros... Stage IIIC Pros... | Biospecimen Col... Carboplatin Chest Radiograp... Computed Tomogr... Magnetic Resona... PSMA PET Scan Surgical Proced... | 18 Years - | SWOG Cancer Research Network | |
| Trial of NanoPac Focal Therapy for Prostate Cancer | NCT04221828 | Prostate Cancer Prostate Adenoc... Prostate Cancer... Prostatic Neopl... Urogenital Neop... Genital Neoplas... Localized Cance... | NanoPac (steril... | 18 Years - | NanOlogy, LLC | |
| Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer | NCT04428203 | Prostate Cancer... Prostate Cancer Prostate Adenoc... | Epidiolex Oral ... | 18 Years - | University of Kentucky | |
| Phase II Trial of SBRT + or - IMRT in Treatment of Patients With Clinically Confined Prostate Adenocarcinoma | NCT02339948 | Prostate Adenoc... | SBRT | 18 Years - | GenesisCare USA | |
| Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer | NCT03796767 | Recurrent Prost... Metastatic Mali... Metastatic Mali... Oligometastasis Prostate Adenoc... PSA Failure | Hypofractionate... Intensity-Modul... Metastasectomy Quality-of-Life... Questionnaire A... Stereotactic Bo... | 18 Years - | University of Utah | |
| 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | NCT03805594 | Castration Leve... Castration-Resi... Metastatic Pros... Prostate Adenoc... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Lutetium Lu 177... Pembrolizumab | 18 Years - | University of California, San Francisco | |
| Defining Recurrent Disease With Axumin™ | NCT03996993 | Prostate Cancer Prostate Adenoc... | Casodex, Axumin Salvage Radiati... | 18 Years - | Cancer Center of Irvine | |
| 68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer | NCT02624518 | Prostate Adenoc... | 68Ga-RM2 Magnetic Resona... Positron Emissi... | 18 Years - | Stanford University | |
| Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer | NCT02692105 | Prostate Cancer | Low dose rate p... High Dose Rate ... | 40 Years - 80 Years | British Columbia Cancer Agency | |
| Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement | NCT00869206 | Breast Adenocar... DS Stage I Plas... DS Stage II Pla... Metastatic Mali... Pain Musculoskeletal... Urinary Complic... | zoledronic acid | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer | NCT02692105 | Prostate Cancer | Low dose rate p... High Dose Rate ... | 40 Years - 80 Years | British Columbia Cancer Agency | |
| Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy | NCT04915508 | Prostate Adenoc... Stage IIIB Pros... Stage IIIC Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Hormone Therapy Stereotactic Bo... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score | NCT05050084 | Prostate Adenoc... | Bicalutamide Buserelin Darolutamide Degarelix Flutamide Goserelin Histrelin Leuprolide Radiation Thera... Relugolix Triptorelin | 18 Years - | NRG Oncology | |
| Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer | NCT03821792 | Metastatic Pros... Prostate Adenoc... Prostate Carcin... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Abiraterone Ace... Apalutamide Prednisone | 18 Years - | M.D. Anderson Cancer Center | |
| Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer | NCT01120236 | Prostate Adenoc... Recurrent Prost... Stage IV Prosta... | Bicalutamide Cixutumumab Goserelin Aceta... Laboratory Biom... Leuprolide Acet... Pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer | NCT03649841 | Castration-Sens... Metastatic Mali... Metastatic Pros... Prostate Adenoc... Prostate Small ... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Antiandrogen Th... Abiraterone Ace... Prednisone Radiation Thera... | 18 Years - | University of Washington | |
| CCRO044: Quality of Life Assessments Associated With a Physician Communication Intervention for Prostate Cancer Patients | NCT03780023 | Prostate Adenoc... | Questionnaire | 18 Years - | University of California, Davis | |
| Effect of Treatment on Work Experience in Patients With Stage I-III Prostate Cancer | NCT03963739 | Prostate Adenoc... Stage I Prostat... Stage II Prosta... Stage III Prost... | Interview Questionnaire A... | 18 Years - | Wake Forest University Health Sciences | |
| Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel | NCT02491411 | Hormone-Resista... Metastatic Pros... Prostate Adenoc... Stage IV Prosta... | Dexamethasone Enzalutamide Laboratory Biom... Quality-of-Life... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| SBRT With Focal Dose Escalation on DIL in Localized Prostate Cancer | NCT05919524 | Prostate Adenoc... | Prostate SBRT (... | 18 Years - | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | |
| Two StereoTactic Ablative Adaptive Radiotherapy Treatments for Localized Prostate Cancer | NCT02031328 | Prostate Adenoc... | Stereotactic Ab... | 18 Years - | Sunnybrook Health Sciences Centre | |
| Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement | NCT00869206 | Breast Adenocar... DS Stage I Plas... DS Stage II Pla... Metastatic Mali... Pain Musculoskeletal... Urinary Complic... | zoledronic acid | 18 Years - | Alliance for Clinical Trials in Oncology | |
| 5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT) | NCT04610372 | Oligometastatic... | Hypofractionate... High dose rate ... Permanent seed ... Stereotactic bo... | 18 Years - | British Columbia Cancer Agency | |
| MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy | NCT05710380 | Prostate Cancer Prostate Adenoc... Prostate Neopla... | Risk Map Decisi... Magnetic Resona... Magnetic Resona... | 18 Years - | University of Chicago | |
| Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Patients With Prostate Adenocarcinoma | NCT03718338 | Prostate Adenoc... | Evaluation Quality-of-Life... | - | University of Washington | |
| Initial Experience in Brazilian Single Center With High Intensity Focalized Ultrasound (HIFU) Prostate Cancer Therapy: Morbidity, Oncological and Functional Outcomes. | NCT03255135 | Prostate Cancer Prostate Adenoc... Transrectal Hig... | HIFU | 30 Years - | Hospital de Transplante Doutor Euryclides de Jesus Zerbini | |
| Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors | NCT03880422 | Cancer Survivor Obesity Overweight Prostate Adenoc... Stage A Prostat... Stage B Prostat... Stage C Prostat... Stage D Prostat... Stage I Prostat... Stage II Prosta... Stage IIA Prost... Stage IIB Prost... Stage IIC Prost... Stage III Prost... Stage IIIA Pros... Stage IIIB Pros... Stage IIIC Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Dietary Interve... Educational Int... Exercise Interv... Quality-of-Life... Survey Administ... | 18 Years - | Roswell Park Cancer Institute | |
| Radiotherapy Plus Hormone Therapy in Biochemically-relapsing Prostate Cancer Patients Following Surgery | NCT01780220 | Biochemically-r... | Abiraterone | 18 Years - | UNICANCER | |
| Phase II Trial of SBRT + or - IMRT in Treatment of Patients With Clinically Confined Prostate Adenocarcinoma | NCT02339948 | Prostate Adenoc... | SBRT | 18 Years - | GenesisCare USA | |
| Enzalutamide Implants (Enolen) in Patients With Prostate Cancer | NCT06257693 | Prostate Adenoc... | enzalutamide | 21 Years - | Alessa Therapeutics Inc. | |
| CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer | NCT01985828 | Prostate Adenoc... | CyberKnife Androgen Depriv... Intensity Modul... | 18 Years - | Advocate Health Care | |
| ERG Protein Expression in Prostatic Adenocarcinoma and Its Clinicopathological Features | NCT04825691 | Prostate Adenoc... | Immunohistochem... | 50 Years - 90 Years | Assiut University | |
| Defining Recurrent Disease With Axumin™ | NCT03996993 | Prostate Cancer Prostate Adenoc... | Casodex, Axumin Salvage Radiati... | 18 Years - | Cancer Center of Irvine | |
| Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study | NCT05960578 | Castration-Resi... Prostate Adenoc... | Apalutamide Biopsy Biospecimen Col... Computed Tomogr... Golimumab Magnetic Resona... PSMA PET Scan | 18 Years - | University of Washington | |
| Focal Laser Ablation of Low to Intermediate Prostate Cancer Tumors | NCT02600156 | Prostate Cancer Prostate Adenoc... Stage I Prostat... Stage II Prosta... Localized Prost... | Focal laser abl... | 45 Years - | Mayo Clinic | |
| Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion | NCT04976257 | Prostate Adenoc... Prostate Carcin... Stage IIC Prost... Stage III Prost... Stage IIIA Pros... Stage IIIB Pros... Stage IIIC Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Angiogram Catheterization Gallium Ga-labe... Positron Emissi... | 18 Years - 80 Years | University of California, San Francisco | |
| Reduction of Gastrointestinal Toxicity in Prostate Cancer by Proton Spot Placement | NCT06200259 | Prostate Cancer Prostate Adenoc... Prostate Carcin... | Spot Delete pla... Traditional pro... | 18 Years - | Thompson Cancer Survival Center | |
| Patients Overexposed for a Prostate Adenocarcinoma | NCT00773656 | Prostate Adenoc... | Whole blood sam... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial | NCT06022822 | Prostate Adenoc... | Biopsy Biospecimen Col... Placebo Adminis... Urolithin A Sup... | 18 Years - | National Cancer Institute (NCI) | |
| Reduction of Gastrointestinal Toxicity in Prostate Cancer by Proton Spot Placement | NCT06200259 | Prostate Cancer Prostate Adenoc... Prostate Carcin... | Spot Delete pla... Traditional pro... | 18 Years - | Thompson Cancer Survival Center | |
| 68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment | NCT02673151 | Prostate Adenoc... PSA Failure Recurrent Prost... | Computed Tomogr... 68Ga-PSMA-11 Positron Emissi... | 18 Years - | Stanford University | |
| Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer | NCT03361735 | Prostate Adenoc... | Leuprolide Acet... Goserelin Aceta... Stereotactic Bo... Radium Ra 223 D... Laboratory Biom... Degarelix | 18 Years - | City of Hope Medical Center | |
| Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer | NCT00170157 | Prostate Adenoc... Prostate Carcin... Recurrent Prost... Stage III Prost... Stage IV Prosta... | Bicalutamide Flutamide Goserelin Aceta... Ipilimumab Leuprolide Acet... Pharmacological... | 18 Years - | Mayo Clinic | |
| CT-guided Stereotactic Body Radiation Therapy and MRI-guided Stereotactic Body Radiation Therapy for Prostate Cancer, MIRAGE Study | NCT04384770 | Prostate Adenoc... | CT-guided Stere... MRI-guided Ster... Questionnaire A... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes | NCT03762759 | Prostate Adenoc... | Computed Tomogr... Fluciclovine F1... Gallium Ga68-la... Positron Emissi... | 18 Years - | Emory University | |
| Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Screening Prostate Cancer | NCT05055843 | Prostate Adenoc... Prostate Carcin... | Magnetic Resona... | 18 Years - | M.D. Anderson Cancer Center | |
| Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer | NCT03516812 | Castration-Resi... Prostate Adenoc... | Laboratory Biom... Olaparib Quality-of-Life... Survey Administ... Testosterone En... Testosterone Cy... | 18 Years - | University of Washington | |
| A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer | NCT05027477 | Prostate Cancer Prostate Adenoc... | Radical Prostat... TULSA Procedure | 40 Years - 80 Years | Profound Medical Inc. | |
| Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors | NCT03880422 | Cancer Survivor Obesity Overweight Prostate Adenoc... Stage A Prostat... Stage B Prostat... Stage C Prostat... Stage D Prostat... Stage I Prostat... Stage II Prosta... Stage IIA Prost... Stage IIB Prost... Stage IIC Prost... Stage III Prost... Stage IIIA Pros... Stage IIIB Pros... Stage IIIC Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Dietary Interve... Educational Int... Exercise Interv... Quality-of-Life... Survey Administ... | 18 Years - | Roswell Park Cancer Institute | |
| Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer | NCT03581500 | Prostate Adenoc... PSA Level Great... Stage IIB Prost... Stage III Prost... Stage IIIA Pros... Stage IIIB Pros... Stage IIIC Pros... Stage IV Prosta... Stage IVA Prost... Stage IVB Prost... | Hyperpolarized ... Magnetic Resona... | - | M.D. Anderson Cancer Center | |
| Early and Accurate Detection of Prostate Cancer in General Practice | NCT03431753 | Prostate Cancer Prostate Neopla... Prostate Adenoc... | PSA, STHLM3 and... | 50 Years - 69 Years | University of Aarhus | |
| MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy | NCT05710380 | Prostate Cancer Prostate Adenoc... Prostate Neopla... | Risk Map Decisi... Magnetic Resona... Magnetic Resona... | 18 Years - | University of Chicago | |
| Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study | NCT04175431 | Prostate Adenoc... | Positron Emissi... Lymphadenectomy Radiation Thera... Abiraterone Ace... Prednisone Computed Tomogr... Abiraterone PSMA PET Scan | 18 Years - | University of Washington | |
| Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer | NCT01786265 | Prostate Adenoc... Recurrent Prost... | Abiraterone Ace... Bicalutamide Degarelix Flutamide Goserelin Aceta... Leuprolide Acet... Nilutamide Prednisone | 18 Years - | M.D. Anderson Cancer Center | |
| A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer | NCT03246347 | Prostate Cancer Prostate Adenoc... | ADT+Docetaxel+E... | 18 Years - | Wake Forest University Health Sciences | |
| Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy | NCT03860961 | Cancer Survivor Prostate Adenoc... | Questionnaire A... Survivorship Ca... Treatment Plan | 18 Years - | NRG Oncology | |
| MRI-Based Active Surveillance to Avoid the Risks of Serial Biopsies in Men With Low-Risk Prostate Ca | NCT02564549 | Prostate Cancer Prostate Adenoc... Multiparametric... Gleason's Score... | TRUS-guided bio... mpMRI with targ... | 40 Years - | Virginia Commonwealth University | |
| Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors | NCT02285101 | Melanoma Prostate Adenoc... | PEG-BCT-100 | 18 Years - | Bio-Cancer Treatment International Limited | |
| Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer | NCT02168062 | Prostate Adenoc... | Behavioral Diet... Counseling Educational Int... Exercise Interv... Goserelin Aceta... Laboratory Biom... Leuprolide Acet... Quality-of-Life... Triptorelin Pam... | - | University of California, San Francisco | |
| Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer 2.0 | NCT04045717 | Prostate Adenoc... Prostate Cancer Prostate Neopla... | Hypo-FLAME 2.0 ... | 18 Years - | Universitaire Ziekenhuizen KU Leuven | |
| Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer | NCT05779943 | Prostate Adenoc... Recurrent Prost... | Furosemide F18-rhPSMA-7.3 Positron Emissi... Computed Tomogr... | 18 Years - | Emory University | |
| Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain | NCT05803096 | Prostate Diseas... Malignancy Benign Prostati... Prostate Cancer Prostate Adenoc... Anxiety and Fea... Pain | Self-Administer... Oxygen | 18 Years - 85 Years | Beth Israel Deaconess Medical Center | |
| Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors | NCT03982173 | Metastatic Colo... Triple Negative... Prostate Adenoc... Stomach Adenoca... Esophageal Aden... | Tremelimumab Durvalumab | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Phase 2 Hypofractionation Study Using Proton Beam Therapy for Prostate Adenocarcinoma | NCT01709253 | Prostate Adenoc... | proton beam the... | - | National Cancer Center, Korea | |
| 68Ga-PSMA-11 PET in Patients With Prostate Cancer | NCT05197257 | Prostate Cancer Prostate Adenoc... | Ga-PSMA-11 | 18 Years - 100 Years | University of Colorado, Denver | |
| A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer | NCT05726292 | Prostate Cancer Prostate Adenoc... | Relacorilant Enzalutamide Placebo (Sugar ... Androgen Depriv... Radical Prostat... | 18 Years - | University of Chicago | |
| A Behavioral Health Intervention Using Digital Technology in Radiation Therapy for Prostate Cancer Patients | NCT04946214 | Prostate Cancer Prostate Adenoc... Radiation Toxic... | Smart Water Bot... | 18 Years - 80 Years | University of Miami | |
| Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy | NCT03821246 | Prostate Adenoc... Prostate Cancer Localized Prost... | Atezolizumab Tocilizumab Etrumadenant | 18 Years - | University of California, San Francisco | |
| 68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery | NCT03368547 | Prostate Adenoc... Stage IIB Prost... Stage III Prost... Stage IV Prosta... | Computed Tomogr... Gallium Ga 68 G... Positron Emissi... | - | Jonsson Comprehensive Cancer Center | |
| Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer | NCT02206334 | Male Breast Car... Prostate Adenoc... Recurrent Breas... Recurrent Non-S... Recurrent Prost... Stage IV Breast... Stage IV Non-Sm... Stage IV Prosta... | Stereotactic Bo... | 18 Years - | NRG Oncology | |
| Prostate Advances in Comparative Evidence | NCT01584258 | Prostate Cancer | Prostatectomy Conventionally ... Prostate SBRT | 18 Years - | Royal Marsden NHS Foundation Trust | |
| C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma | NCT01530269 | Prostate Cancer Prostate Adenoc... | C11-Sodium Acet... | 18 Years - 90 Years | Phoenix Molecular Imaging |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
